Gossamer Bio (GOSS) stock

Worth $5.5BShares as of Aug 8

$11.28

+5.97%

As of Tuesday's close · Live for Pro members at the open

Not scored

Breakaway doesn't score GOSS. It is too thinly traded for a fair Quality Score.

Healthcare · Biotech

Next2026“…following its initial review of the application, which the Company anticipates could occur later this year…”Filing with regulators · SEC filing · Sep 23

Follow GOSS's trial news. Pro members can get an alert when Gossamer Bio files news, and see its trials, share raises, and its CEO's filings.

Get an alert when GOSS files news on its trialSee it live, free until Thursday morning. No account. No card. Then keep going with a free account.

We do the work for you. 3,168 stocks are scored and ranked, every 15 seconds while the market is open. Pro members see it live.

What's next for GOSS, and how long its cash lasts

Next step the company has named

2026“The FDA will determine whether to accept the NDA for filing following its initial review of the application, which the Company anticipates could occur later this year.”Filing with regulators · SEC filing · Sep 23

What it means: a filing asks regulators to approve a drug for sale. Once it is complete and accepted, the FDA sets a decision date, and we show it here.

A trial underway: Open-label Extension Study of Seralutinib in Adult Subjects With PAHPhase 3 · Recruiting · 330 people · main data estimated Dec 2026 · NCT06274801

For Pro members: 43 filings.

Cash runway

The company says its cash lasts into 2028 (8-K, Aug 21).

That is the company's estimate. Our arithmetic on its latest balance sheet reads differently, so we show its words, not ours.

For Pro members: the cash on hand, the cash used each quarter, and the math.

Dilution on the horizon

Shelf registration (S-3ASR, filed Jan 28, 2026)

For Pro members: the amounts, and the share count against a year ago.

Insiders

No open-market buys or sales by its officers or directors in their filings of the last year.

From Form 4: open-market buys and sales only.

Get an alert when Faheem Hasnain buys or sells

For Pro members: every trade, and Faheem Hasnain’s 13 filings and quotes.

Get an alert when GOSS files news on its trialA free account. No card.

See every upcoming FDA date →

FDA dates in the next 60 days

Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.

DateStockDrug

In 12 daysFDA decisionIn 12 days · FDA decisionCAPRCapricor TherapeuticsDeramiocelCAPRCapricor Therapeutics · $500MDeramiocelFDA decision due (PDUFA)
In 12 daysFDA decisionIn 12 days · FDA decisionSVRASavaraMolgramostimSVRASavara · $900MMolgramostimFDA decision due (PDUFA)
In 42 daysFDA decisionIn 42 days · FDA decisionMLYSMineralys TherapeuticsLorundrostatMLYSMineralys Therapeutics · $1.3BLorundrostatFDA decision due (PDUFA)

14 more FDA dates and 103 trial data dates in the next 60 days, each on the FDA calendar. Pro members see whether each company's cash lasts past its date, with an optional alert before it. See all 151 dates, ranked →

GOSS's latest filings

Gossamer Bio Announces Third Quarter 2026 Financial Results and Provides Business Update8-K, filed Nov 10
Quarterly report10-Q, filed Nov 10
7 insider filingsForm 4, filed Sep 25

32 more filings in the last year, for Pro members

From SEC EDGAR, as filed. Each opens the filing on the SEC's site.

Why GOSS isn't scored

The Quality Score reads US-listed stocks worth $50M or more that trade at $1 or more and 300,000 shares or $10M a day. GOSS trades about 193,000 shares a day. A stock that clears every mark is scored from the next weekly rebuild.

Straight AnswersStraight Answers

Are the prices delayed?

Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.